TVGN: Tevogen Bio Company Short-Term Debt

TVGN (Tevogen Bio Inc.) - company brandmark

The price chart for Tevogen Bio Holdings (TVGN) demonstrates the performance of the company, which specializes in innovative treatments for nervous system pathologies, where short-term debt is fixed at 0.00. The business relies on the creation of affordable T-cell drugs for the therapy of oncology and infections. The current stage of clinical trials precludes profit scaling, while the maintenance of laboratories leads to a constant cash drain with zero operating leverage.

tevogen.com (TVGN) - Amount of Current Liabilities from 02/21/2024 to 11/01/2026

Tevogen Bio Inc. - analytical breakdowns and key metrics (TVGN)

- current quotes and average value forecast:
Price Chart Tevogen Bio|TVGN - Fair Value Consensus
- market capitalization information:
Market Value Tevogen Bio Holdings|TVGN - Total Enterprise Value
- shareholders' equity book value data:
Accounting Value per Share Tevogen Bio|TVGN - Total Net Assets|Market Capitalization to Book Value Ratio tevogen.com|TVGN - Company Assets
- debt and liquidity details:
Total Debt to Equity Ratio Tevogen Bio Holdings|TVGN - Long-Term Debt to Equity|Short-Term Debt to Equity Tevogen Bio Holdings|TVGN - Company Cumulative Debt|Debts to Book Capitalization Tevogen Bio Holdings|TVGN - Long-Term Indebtedness|Company Short-Term Debts Tevogen Bio|Quick Liquidity tevogen.com
- earnings and valuation multiples indicators:
TVGN - Company Profit
Basic company analysis:Tevogen Bio (TVGN)
Flagship merchandise of Tevogen Bio Holdings

Investors are seeking fundamental markers of issuer resilience during periods of market stagnation. This metric measures the aggregate of obligations due for repayment within twelve months. Analyzing the volume of short-term debt capital allows for the identification of potential liquidity gaps. For Tevogen Bio Holdings (TVGN), which is currently in the FDA clinical trial stage, rising debt is critical due to the absence of commercial revenue. A high debt load coupled with limited capital inflows jeopardizes the development of the biotech ecosystem.

Analysis of competing companies

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|Company Current Liabilities ACAD|XENE (xenon-pharma.com) - Amount of Current Liabilities|Company Short-Term Debts VKTX|SUPN - Short-Term Debt|Catalyst Pharmaceuticals Inc - Company Current Liabilities|Denali Corp - Company Short-Term Debt|HRMY - Company Short-Term Debt|Short-Term Debt biohavenpharma.com|AMLX: Company Short-Term Debts|Short-Term Indebtedness Trevi Therapeutics Inc TRVI|PRAX (Praxis Medicines) - Company Short-Term Debts|Short-Term Debt Anavex Life Sciences Corp AVXL|Company Short-Term Debt CeriBell, Inc. (CBLL)|Prothena Corporation plc - Company Short-Term Indebtedness|Alector - Company Current Liabilities|Company Short-Term Loans and Borrowings ANNX|Omeros Corp. - Company Short-Term Debts|NGNE: Company Short-Term Debt|ACIU: Company Short-Term Debts|VYGR - Short-Term Debt Volume|Company Short-Term Debt Neumora Therapeutics, Inc.|Short-Term Debt Scilex Holding SCLX|Company Current Liabilities ACOG (Alpha Cognition)|CGTX (cogrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts IKT (Inhibikase Therapeutics)|Company Short-Term Loans and Borrowings SAVA|ASRT - Company Short-Term Debt|Short-Term Debt Coya Therapeutics, Inc.|vistagen.com (VTGN) - Company Short-Term Debt|OVID (Ovid Therapeutics) - Company Short-Term Debt|ABOS (Acumen Pharmaceuticals) - Company Short-Term Debts|Company Short-Term Indebtedness CRVO (cervomed.com)|Company Short-Term Debts ATHE|Short-Term Debt Volume clene.com|Company Short-Term Debt PepGen PEPG|JUNS: Company Short-Term Indebtedness|Relmada Therapeutics - Company Short-Term Debts|Short-Term Indebtedness annovisbio.com (ANVS)|gracetx.com (GRCE) - Company Short-Term Debt|AIFF - Short-Term Debt Volume|Company Current Liabilities KLTO|NRSN (NeuroSense Therapeutics, Ltd.) - Amount of Current Liabilities|Company Current Liabilities RVPH (Reviva Pharmaceuticals)|Company Short-Term Debt MTVA (metaviatx.com)|Company Short-Term Debts NRXS (NeurAxis)|Short-Term Indebtedness Helius Medical Technologies, Inc.|PASG - Company Short-Term Debt|NEUP (Neuphoria Therapeutics Inc.) - Company Short-Term Indebtedness|Minerva Neurosciences (NERV) - Company Short-Term Debt|Company Short-Term Indebtedness ATHA|ADXN (Addex Therapeutics Ltd) - Company Short-Term Debts|Short-Term Debt Alzamend ALZN|Company Current Liabilities CYCN (Cyclerion Therapeutics)|Company Short-Term Debts protagenic.com (PTIX)|Company Short-Term Debt Pasithea Therapeutics Corp. KTTA|Company Short-Term Loans and Borrowings CRGT|ATXI - Company Short-Term Debt|Short-Term Debt Brainstorm Cell Therapeutics Inc.|CARA (Cara Therapeutics, Inc) - Company Current Liabilities|CHRO: Amount of Current Liabilities|ELYM (Eliem Therapeutics, Inc.) - Company Short-Term Debts|Short-Term Debt Intra-Cellular ITCI|Company Current Liabilities LBPH (Longboard Pharmaceuticals, Inc.)|Company Short-Term Debt MRNS (Marinus Pharmaceuticals Inc)|Company Short-Term Debt NKGen NKGN|NeuroBo Pharma (NRBO) - Short-Term Debt|Sage Therapeutics, Inc. - Company Short-Term Debts|Short-Term Indebtedness synaptogen.com (SNPX)|TRVN: Company Short-Term Debts|Short-Term Debt Vigil Neuroscience, Inc. (VIGL)|Company Short-Term Debt Anew Medical, Inc.|Company Short-Term Indebtedness CERE (Cerevel Corp)